Earlier this week, global pharmaceutical company Allergan announced it had broken ground on a $200 million expansion of its facility in Waco, TX, which is currently Allergan's flagship manufacturing facility for eye care products Restasis®, Lumigan®, Combigan®, Refresh Plus®, Refresh Tears® and Latisse®. Once completed, the expansion will reportedly double the current manufacturing space of the facility and increase its production capacity by more than 50 percent.
Click here to read the full press release.
And Allergan also recently announced it had acquired topical dermatology company Topokine Therapeutics. Under terms of the agreement, Allergan acquired Topokine Therapeutics for an upfront payment of $85 million and success-based development and sales milestones for XAF5 — a first-in-class topical agent in late-stage development for the treatment of steatoblepharon, also known as undereye bags.
Click here to read the full press release.